NCT05639322View on ClinicalTrials.gov

Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

October 15, 2025

Study Completion Date

December 15, 2026

Conditions
Neuropathic Pain
Interventions
DRUG

Ketamine Hydrochloride

Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.

BEHAVIORAL

Cognitive Behavioral Therapy

Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12

OTHER

Ketamine + Cognitive Behavioral Therapy

Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.

Trial Locations (1)

M5B 1W8

RECRUITING

St. Michael's Hospital, Toronto

All Listed Sponsors
lead

Unity Health Toronto

OTHER